Results, forecasts and guidance revisions from Japan's listed companies, in English.
Otsuka Holdings lifted its year-to-December core profit forecast to ¥500bn from ¥470bn, with a newly launched IgA nephropathy drug and its antipsychotic offsetting a 31.1% nine-month sales fall in its kidney-disease drug after US generic entry.
Murata raised its full-year operating-profit forecast to ¥520bn from ¥430bn, crediting data-centre demand, higher production volume and product mix, with the second-half assumption of ¥155 to the dollar unchanged.
Mitsubishi Electric posted record first-half sales and adjusted operating profit on factory-automation, chip and air-conditioning demand, raised its annual adjusted profit guide to ¥710bn and decided on a buyback of up to ¥200bn.
Members says AI substitution and customer spending cuts cost it about ¥550mn of planned half-year revenue, pushing it to a ¥389mn operating loss even as sales rose 3.0%, and its ¥200mn full-year profit target counts no revenue from higher AI-transformation orders.
Joshin raised its forecast for operating profit in the year to March 2027 to ¥11bn from ¥6bn, crediting early air-conditioner purchases ahead of a 2027 environmental-rule change and solid sales of other home appliances.
DMG MORI booked a record ¥186.8bn of orders in July–September and raised its full-year order outlook to ¥650bn or more, but annual revenue and profit guidance are unchanged and a prior-year insurance gain distorts net-profit comparisons.
Daiwa's half-year ordinary profit rose 69.9% to ¥166.4bn, while the ¥385.2bn ORIX Bank purchase added ¥103.45bn of goodwill, amortised over 20 years, and enlarged the group's loan and deposit books.
Chiba Kogyo Bank reported gross unrealized losses of ¥19.685bn on its held-to-maturity bonds at end-September, ¥19.683bn net of gains, while gains on other securities outweighed them and its earnings and dividend forecasts for the year to March 2027 stay unchanged.
TEPCO's ¥52.7bn interim net profit follows a ¥712.4bn loss a year earlier, but the business posted a ¥33.7bn operating loss and negative operating cash flow, and the full-year forecast stays undecided.
Takeda's half-year net profit rose 171.6% on a 4.1% effective tax rate, yet core operating profit grew just 0.7% at constant currency, even as the drugmaker raised its full-year profit forecasts.
Renesas's nine-month IFRS operating profit of ¥758.0bn includes a ¥450.3bn gain on selling its Timing business, while its Non-GAAP measure shows ¥408.7bn and third-quarter sales up 30.2%.
Osaka Gas raised its full-year sales forecast by ¥84bn to ¥2.25tn while holding ordinary profit guidance at ¥190bn, after a delay in passing fuel costs into gas tariffs cut interim ordinary profit by 21.6%.
Oriental Land's April to September operating profit of ¥78.5bn beat its ¥58.9bn forecast, and the Tokyo Disney Resort operator raised its full-year profit guide and annual dividend forecast to ¥18 a share.
Nippon Yusen lifted its forecast for net profit in the year to March 2027 by ¥90bn to ¥330bn, citing stronger container rates at affiliate ONE, while operating profit is guided up only ¥25bn to ¥210bn.
Nomura Research Institute lifted its operating profit guide for the year to March 2027 to ¥180bn, citing demand for AI-premised system modernisation and digital security, while cutting its consulting revenue forecast to ¥66bn.
Kurita Water Industries cut its full-year business-profit forecast to ¥40.0bn from ¥61.5bn after design delays and required module rebuilds on one US electronics-industry project pushed estimated costs above the order value, while raising its sales guide.
Konami lifted its forecast for the year to March 2027 to ¥583bn in sales and ¥200bn in business profit, up from ¥505bn and ¥150bn, saying first-half results ran ahead of plan and eFootball and Yu-Gi-Oh performed well, and raised its dividend forecast to ¥299.
Komatsu lifted its full-year operating profit forecast to ¥585bn as demand beat plan across many regions, while the July-September margin fell to 12.1% and April-September construction and vehicles sales dropped in the Middle East, Asia and Japan.
Kissei Pharmaceutical lifted its interim operating profit forecast to ¥1.6bn from ¥500mn, but cut net profit to ¥5.1bn from ¥7.4bn after factoring in special losses on assets for a drug facing approval-revocation proceedings.
Keyence's first-half operating profit rose 50.0% to ¥408.3bn on a 34.9% rise in sales, and the company lifted its interim dividend to ¥325 before a five-for-one share split on November 21.
Imperial Hotel's interim sales rose 10.2% to ¥28.01bn, but Kyoto start-up costs and Tower building reopening spending cut operating profit 59.5% to ¥129mn, though results beat the company's May forecast and full-year guidance is unchanged.
Chubu Electric wrote off its nuclear power business assets, a ¥370.3bn special loss, after withdrawing Hamaoka Units 3 and 4 permit applications, and now forecasts a ¥215.0bn net loss for the year to March 2027.
Anritsu raised its operating-profit forecast to ¥22bn on strong optical-transceiver test demand and lifted its annual dividend forecast to ¥63, while guiding its environmental-measurement unit to a ¥1.2bn loss after a goodwill write-down.
A weaker yen lifted Aisin's half-year sales 7.3%, but operating profit fell 16.3% on higher material costs, earthquake expenses and weaker China volumes, and the supplier lowered its full-year operating profit forecast to ¥215bn.